The Kiadis Pharma product pipeline is focused on providing novel treatments for significant unmet medical needs in the field of bone marrow transplants and the treatment of aggressive cancers. The four most advanced products are currently in clinical trials, ranging from Phase I to entering Phase III. Kiadis Pharma's lead product is ATIR, which enables the use of mismatched bone-marrow donors in transplantations for terminally ill blood cancer patients. Kiadis Pharma is a Dutch company with locations in The Netherlands and Canada.
Ekaterina Smirnyagina, of Alta Partners, joining the Supervisory Board of Kiadis, added: "We were impressed by the broad endorsement of Kiadis' clinical programs within the international scientific community. Its lead product, ATIR, is being tested by opinion leaders in the field as a potentially life-saving treatment option for patients unable to find a matched bone-marrow donor, while also preventing graft-versus-host disease (GvHD). We look forward to working with the seasoned management of Kiadis and its investors on building a premier oncology company".
Mark Wegter, Chairman of the Supervisory Board of Kiadis Pharma and General Partner at LSP, commented: "Following the acquisition of Celmed late last year, this is yet again a key milestone that has been achieved by the company and its management. It marks the next step in the further growth of Kiadis Pharma which we feel is positioned to become a major force in the European biotech arena. We are very pleased to see our excitement about the company being shared by other high quality US and European investors."
Manja Bouman, CEO, Kiadis Pharma, stated: "We are delighted by this latest funding round. Our shareholders provide a particularly strong knowledge base with an excellent track record in life sciences. Bringing in Alta Partners as our lead investor is an important external validation. Not only does it confirm the potential of many of our clinical trials, but it also demonstrates the overall confidence of sophisticated investors in our novel treatments."
She added: "Earlier this year we announced the trial of our ATIR product on nine end-stage blood cancer patients who were transplanted in the mismatched setting with the use of ATIR. All patients responded well. This treatment is at a very exciting stage in its development and this trial was an important milestone in our revolutionary approach to providing successful mismatch transplants for end stage blood cancer patients."
About Kiadis Pharma
Kiadis Pharma is an oncology focused pharmaceutical company with four programs in different phases of clinical development. The company develops products that offer new treatment options for terminally ill cancer patients and address significant unmet medical needs. Key areas for Kiadis Pharma are clinical indications in blood cancers and solid tumors. Kiadis Pharma is headquartered in the Netherlands with facilities in Groningen, the Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit www.kiadis.com
About Alta Partners
Alta Partners is a San Francisco-based venture capital firm focused on life sciences investing. Founded in 1996, the firm currently manages $2 billion in committed capital through eight venture fund programs. Alta invests in life sciences companies across the development continuum, from company formation to later-stage opportunities, and has funded more than 110 companies in the sector to date. www.altapartners.com
About LSP
LSP (Life Sciences Partners) is a leading independent European-headquartered venture capital firm, providing private equity financing to early- to mid-stage life-science companies. With EUR 400 million under management and offices in Amsterdam, Munich and Boston. For more information about the LSP Group, please visit the website at www.lspvc.com
About MedSciences Capital
MedSciences Capital (www.medsciencescapital.com) is an Amsterdam-based investor in early- to mid-stage medical life sciences companies. MedSciences Capital operates as a part of the Dutch merchant bank, Kempen & Co N.V. (www.kempen.nl).
For further information
Kiadis Pharma B.V., Dr. Manja Bouman, CEO, Email: m.bouman@kiadis.com, Telephone: +31 (0)50 547 4270 Alta Partners, Jennifer James, Director of Marketing and Communications, Email: jjames@altapartners.com, Telephone: (415) 362-4022 LSP, Mark Wegter, General partner, Email: mwegter@lspvc.com, Telephone: +31 (0)20 664 5500 MedSciences Capital, Willem van Lawick, MD, MBA, Director, Email: lawick@medsciencescapital.com, Telephone: +31 (0)20 348 8702
Source: Kiadis Pharma
